Vital Therapies (VTL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)
August 6, 2018 9:27 AM EDTToday's Pre-Open Movers
Ovid Therapeutics Inc. (NASDAQ: OVID) 27% LOWER; announced that the Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome. OV101 is the only selective extrasynaptic GABAA receptor agonist in development shown to mediate tonic inhibition, a key underlying pathophysiological mechanism of Angelman syndrome. Ovids founder, president and chief scientific officer, Matthew During, M.D., DSc, FACP, will present the data today at the 2018 Angelman Syndrome... More
UPDATE: William Blair Upgrades Vital Therapies (VTL) to Outperform
August 6, 2018 4:58 AM EDT(Updated - August 6, 2018 8:14 AM EDT)
(updated to expand analyst comment)
William Blair upgraded Vital Therapies (NASDAQ: VTL) from Market Perform to Outperform.
Analayst Y. Katherine Xu is incrementally more positive on the equity ahead of VTL-308 readout scheduled for... More
